<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39468309</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Clinical usefulness of the serum levels of neuroinflammatory and lung fibrosis biomarkers in the assessment of cognitive dysfunction in post-COVID19 patients.</ArticleTitle><Pagination><StartPage>25798</StartPage><MedlinePgn>25798</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-76630-4</ELocationID><Abstract><AbstractText>A growing body of evidence indicates there is an increasing incidence of cognitive dysfunction in patients after coronavirus disease 2019 (COVID-19) infection. However, still lack diagnostic tools, which allow us to predict prognosis in such cases and improve the stratification of the disease. This study aims to evaluate the usefulness of the biomarkers that could allow to predict the severity and progression of COVID-19 in patients with post-COVID syndrome and cognitive problems. Data regarding clinical history, pre-existing conditions, chest CT scan, and therapy (remdesivir, steroids) were acquired. A total of 44 patients with hospitalized COVID-19, and healthy controls were enrolled in the investigation, and serum blood was obtained. After 6 months of observations, patients with COVID-19 were divided into two groups: first - without post-COVID syndrome and memory complaints, and second - with post-COVID and cognitive problems. Measurements of YKL-40 and MR-pro-ADM were taken in the serum with enzyme immunoassay kits at the time of admission (visit 1) and 6 months after discharge from the hospital (visit 2). Significantly higher concentrations of YKL-40 were found in patients with COVID-19 as compared to healthy individuals (p = 0.016). Moreover, YKL-40 ratio allowed to differentiate patients with and without post-COVID syndrome (median: 0.94 vs. 1.55, p = 0.004). Additionally, COVID-19 patients with dyspnea presented significantly elevated levels of MR-pro-ADM as compared to the group of COVID-19 survivors without dyspnea (p = 0.015). In the group of patients without post-COVID syndrome, the concentrations of YKL-40 and MR-pro-ADM decreased after treatment as compared to levels before therapy (77 vs. 36 ng/ml and 607 vs. 456 pmol/L). However, in patients with post-COVID syndrome and cognitive problems, the levels of both markers did not alter 6 months after hospital discharge in comparison to basal levels. Furthermore, after dexamethasone treatment the YKL-40 concentrations declined significantly (p = 0.003) in patients with COVID-19. This study demonstrated the predictive usefulness of YKL-40 as an indicator of successful treatment in patients with COVID-19 infection allowing risk stratification of hospitalized patients. It seems that indicators of neuroinflammation might have the potential to track development of cognitive complaints, however, it requires further investigations.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kulczyńska-Przybik</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurodegeneration Diagnostics, Medical University of Białystok, 15-269, Białystok, Poland. agnieszka.kulczynska-przybik@umb.edu.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Czupryna</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Neuroinfections, Medical University of Bialystok, 15-540, Białystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adamczuk</LastName><ForeName>Justyna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Neuroinfections, Medical University of Bialystok, 15-540, Białystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kruszewska</LastName><ForeName>Ewelina</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Neuroinfections, Medical University of Bialystok, 15-540, Białystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mroczko</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurodegeneration Diagnostics, Medical University of Białystok, 15-269, Białystok, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemical Diagnostics, Medical University of Białystok, 15-269, Białystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moniuszko-Malinowska</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and Neuroinfections, Medical University of Bialystok, 15-540, Białystok, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071451">Chitinase-3-Like Protein 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C084533">CHI3L1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071451" MajorTopicYN="Y">Chitinase-3-Like Protein 1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011658" MajorTopicYN="N">Pulmonary Fibrosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090862" MajorTopicYN="N">Neuroinflammatory Diseases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cognitive dysfunction</Keyword><Keyword MajorTopicYN="N">MR-pro-ADM</Keyword><Keyword MajorTopicYN="N">YKL-40</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>1</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39468309</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-76630-4</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-76630-4</ArticleId></ArticleIdList><ReferenceList><Title /><Reference><Citation>Calabria, M. et al. Post-COVID-19 fatigue: The contribution of cognitive and neuropsychiatric symptoms. J. Neurol. 269, 3990–3999 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11141-8</ArticleId><ArticleId IdType="pubmed">35488918</ArticleId><ArticleId IdType="pmc">9055007</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban, F. et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav. Immun. 101, 93–135 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker, J. H. et al. Assessment of cognitive function in patients after COVID-19 infection. JAMA Netw. Open 4, e2130645 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.30645</ArticleId><ArticleId IdType="pubmed">34677597</ArticleId><ArticleId IdType="pmc">8536953</ArticleId></ArticleIdList></Reference><Reference><Citation>Crivelli, L. et al. Changes in cognitive functioning after COVID-19: A systematic review and meta-analysis. Alzheimer’s Dementia 18, 1047–1066 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12644</ArticleId><ArticleId IdType="pubmed">35297561</ArticleId></ArticleIdList></Reference><Reference><Citation>Batiha, G. E. S., Al-kuraishy, H. M., Al-Gareeb, A. I. &amp; Welson, N. N. Pathophysiology of post-COVID syndromes: A new perspective. Virol. J. https://doi.org/10.1186/s12985-022-01891-2 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01891-2</ArticleId><ArticleId IdType="pubmed">36210445</ArticleId><ArticleId IdType="pmc">9548310</ArticleId></ArticleIdList></Reference><Reference><Citation>Soung, A. L. et al. COVID-19 induces CNS cytokine expression and loss of hippocampal neurogenesis. Brain 145, 4193–4201 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac270</ArticleId><ArticleId IdType="pubmed">36004663</ArticleId><ArticleId IdType="pmc">9452175</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy, H. M. et al. Mechanistic insight and possible mechanism of seizure in Covid-19: The nuances and focal points. CNS Neurol. Disord. Drug Targets 22, (2022).</Citation></Reference><Reference><Citation>Bajinka, O., Simbilyabo, L., Tan, Y., Jabang, J. &amp; Saleem, S. A. Lung-brain axis. Crit. Rev. Microbiol. 48, 257–269 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1040841X.2021.1960483</ArticleId><ArticleId IdType="pubmed">34348558</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzoni, R. &amp; Marsland, B. J. The lung-brain axis: A new frontier in host-microbe interactions. Immunity. https://doi.org/10.1016/j.immuni.2022.03.015 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.03.015</ArticleId><ArticleId IdType="pubmed">35417673</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuzzo, D. &amp; Picone, P. Potential neurological effects of severe COVID-19 infection. Neurosci. Res.. https://doi.org/10.1016/j.neures.2020.06.009 (2020).</Citation></Reference><Reference><Citation>Montrucchio, G. et al. Effectiveness of mid-regional pro-adrenomedullin (MR-proADM) as prognostic marker in COVID-19 critically ill patients: An observational prospective study. PLoS ONE 16, e0246771 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246771</ArticleId><ArticleId IdType="pubmed">33556140</ArticleId><ArticleId IdType="pmc">7870047</ArticleId></ArticleIdList></Reference><Reference><Citation>Montrucchio, G. et al. Effectiveness of mid-regional pro-adrenomedullin, compared to other biomarkers (including lymphocyte subpopulations and immunoglobulins), as a prognostic biomarker in COVID-19 critically ill patients: New evidence from a 15-month observational prospective. Front. Med. 10, (2023).</Citation></Reference><Reference><Citation>Sozio, E. et al. MR-proADM as prognostic factor of outcome in COVID-19 patients. Sci. Rep. 11, (2021).</Citation></Reference><Reference><Citation>Elke, G. et al. The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis—A secondary analysis of a large randomised controlled trial. Crit. Care 22, 79 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-018-2001-5</ArticleId><ArticleId IdType="pubmed">29562917</ArticleId><ArticleId IdType="pmc">5863464</ArticleId></ArticleIdList></Reference><Reference><Citation>Hupf, J. et al. RNA-expression of adrenomedullin is increased in patients with severe COVID-19. Crit. Care 24, 527 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03246-1</ArticleId><ArticleId IdType="pubmed">32859259</ArticleId><ArticleId IdType="pmc">7453369</ArticleId></ArticleIdList></Reference><Reference><Citation>Fialek, B. et al. Systematic review with meta-analysis of mid-regional pro-adrenomedullin (MR-proadm) as a prognostic marker in Covid-19-hospitalized patients. Ann. Med. 55, 379–387 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2162116</ArticleId><ArticleId IdType="pubmed">36607317</ArticleId><ArticleId IdType="pmc">9828692</ArticleId></ArticleIdList></Reference><Reference><Citation>García de Guadiana-Romualdo, L. et al. Circulating MR-proADM levels, as an indicator of endothelial dysfunction, for early risk stratification of mid-term mortality in COVID-19 patients. Inte. J. Infect. Dis. 111, 211–218 (2021).</Citation></Reference><Reference><Citation>Madden, N. et al. The link between SARS-CoV-2 related microglial reactivity and astrocyte pathology in the inferior olivary nucleus. Front. Neurosci. 17, 1198219 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2023.1198219</ArticleId><ArticleId IdType="pubmed">37483351</ArticleId><ArticleId IdType="pmc">10359900</ArticleId></ArticleIdList></Reference><Reference><Citation>Lananna, B. V. et al. Chi3l1/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer’s disease pathogenesis. Sci. Transl. Med. 12, (2020).</Citation></Reference><Reference><Citation>Ferrari-Souza, J. P. et al. Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease. Mol. Psychiatry 27, 4781–4789 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01716-2</ArticleId><ArticleId IdType="pubmed">35948658</ArticleId><ArticleId IdType="pmc">9734046</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonneh-Barkay, D., Wang, G., Starkey, A., Hamilton, R. L. &amp; Wiley, C. A. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J. Neuroinflamm. 7, 34 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-7-34</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy, S. L. et al. Circulating markers of extracellular matrix remodelling in severe COVID-19 patients. J. Intern Med. 294, 784–797 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13725</ArticleId><ArticleId IdType="pubmed">37718572</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamle, S. et al. Chitinase 3-like-1 is a therapeutic target that mediates the effects of aging in COVID-19. JCI Insight 6, (2021).</Citation></Reference><Reference><Citation>Kamle, S. et al. Host chitinase 3-like-1 is a universal therapeutic target for SARS-CoV-2 viral variants in COVID-19. Elife 11, (2022).</Citation></Reference><Reference><Citation>Sánchez-Díez, S. et al. Biomarker profiles associated with COVID-19 severity and mortality. Curr. Issues Mol. Biol. 45, 1998–2012 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cimb45030128</ArticleId><ArticleId IdType="pubmed">36975498</ArticleId><ArticleId IdType="pmc">10047501</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lorenzo, R. et al. Post-COVID trajectory of pentraxin 3 plasma levels over 6 months and their association with the risk of developing post-acute depression and anxiety. CNS Drugs 38, 459–472 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-024-01081-4</ArticleId><ArticleId IdType="pubmed">38658499</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandala, C. et al. Putative mechanism of neurological damage in COVID-19 infection. Acta Neurobiol. Exp 81, 69–79 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.21307/ane-2021-008</ArticleId></ArticleIdList></Reference><Reference><Citation>Batiha, G. E. S. et al. Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal. Inflammopharmacology. https://doi.org/10.1007/s10787-022-01087-8 (2023).</Citation></Reference><Reference><Citation>Al-kuraishy, H. M. et al. Pirfenidone and post-Covid-19 pulmonary fibrosis: Invoked again for realistic goals. Inflammopharmacology. https://doi.org/10.1007/s10787-022-01027-6 (2022).</Citation></Reference><Reference><Citation>Ramani, A., Pranty, A. I. &amp; Gopalakrishnan, J. Neurotropic effects of SARS-CoV-2 modeled by the human brain organoids. Stem Cell Rep.. https://doi.org/10.1016/j.stemcr.2021.02.007 (2021).</Citation></Reference><Reference><Citation>Ransing, R. et al. Can COVID-19 related mental health issues be measured? Brain Behav. Immunity. https://doi.org/10.1016/j.bbi.2020.05.049 (2020).</Citation></Reference><Reference><Citation>Şahan, E., Ünal, S. M. &amp; Kırpınar, İ. Can we predict who will be more anxious and depressed in the COVID-19 ward? J. Psychosom Res. 140, (2021).</Citation></Reference><Reference><Citation>Al-kuraishy, H. M. et al. Covid-19-induced dysautonomia: A menace of sympathetic storm. ASN Neuro. https://doi.org/10.1177/17590914211057635 (2021).</Citation></Reference><Reference><Citation>Nadwa, E. H. et al. Cholinergic dysfunction in COVID-19: Frantic search and hoping for the best. Naunyn-Schmiedeberg’s Arch. Pharmacol. vol. 396. https://doi.org/10.1007/s00210-022-02346-9 (2023).</Citation></Reference><Reference><Citation>Boyraz, R. K., Şahan, E., Boylu, M. E. &amp; Kırpınar, İ. Predictors of long-term anxiety and depression in discharged COVID-19 patients: A follow-up study. World J. Clin. Cases 10, (2022).</Citation></Reference><Reference><Citation>Serrano-Castro, P. J. et al. The cognitive and psychiatric subacute impairment in severe Covid-19. Sci. Rep. 12, (2022).</Citation></Reference><Reference><Citation>Kimura, Y. et al. Identification of serum prognostic biomarkers of severe COVID-19 using a quantitative proteomic approach. Sci. Rep. 11, (2021).</Citation></Reference><Reference><Citation>De Lorenzo, R. et al. Chitinase-3-like protein-1 at hospital admission predicts COVID-19 outcome: A prospective cohort study. Sci. Rep. 12, 7606 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-11532-x</ArticleId><ArticleId IdType="pubmed">35534648</ArticleId><ArticleId IdType="pmc">9084263</ArticleId></ArticleIdList></Reference><Reference><Citation>Damiano, R. F. et al. Cognitive impairment in long-COVID and its association with persistent dysregulation in inflammatory markers. Front. Immunol. 14, (2023).</Citation></Reference><Reference><Citation>Zhang, N., Yu, X., Xie, J. &amp; Xu, H. New Insights into the Role of Ferritin in Iron Homeostasis and Neurodegenerative Diseases. Mol. Neurobiol.. https://doi.org/10.1007/s12035-020-02277-7 (2021).</Citation></Reference><Reference><Citation>Ruscitti, P. &amp; Giacomelli, R. Ferritin and Severe COVID-19, from clinical observations to pathogenic implications and therapeutic perspectives. Isr. Med. Assoc. (2020).</Citation></Reference><Reference><Citation>Yang, H. et al. Mitochondrial ferritin in neurodegenerative diseases. Neurosci. Res.. https://doi.org/10.1016/j.neures.2013.07.005 (2013).</Citation></Reference><Reference><Citation>Friedman, A., Arosio, P., Finazzi, D., Koziorowski, D. &amp; Galazka-Friedman, J. Ferritin as an important player in neurodegeneration. Parkins. Relat. Disord.. https://doi.org/10.1016/j.parkreldis.2011.03.016 (2011).</Citation></Reference><Reference><Citation>Quintana, C. et al. Study of the localization of iron, ferritin, and hemosiderin in Alzheimer’s disease hippocampus by analytical microscopy at the subcellular level. J. Struct. Biol. 153, (2006).</Citation></Reference><Reference><Citation>de los Monteros, A. E. et al. Dietary iron and the integrity of the developing rat brain: A study with the artificially-reared rat pup. Cell Mol. Biol. 46, (2000).</Citation></Reference><Reference><Citation>Bartzokis, G. et al. Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol. Aging 28, (2007).</Citation></Reference><Reference><Citation>Bartzokis, G. et al. Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: Implications for cognitive decline and dementia. Arch. Gen Psychiatry 63, (2006).</Citation></Reference><Reference><Citation>Sozio, E. et al. Identification of COVID-19 patients at risk of hospital admission and mortality: A European multicentre retrospective analysis of mid-regional pro-adrenomedullin. Respir. Res. 23, (2022).</Citation></Reference><Reference><Citation>Benedetti, I. et al. High levels of mid-regional proadrenomedullin in ARDS COVID-19 patients: The experience of a single, italian center. Eur. Rev. Med. Pharmacol. Sci. 25, (2021).</Citation></Reference><Reference><Citation>Oblitas, C.-M. et al. Mid-regional pro-adrenomedullin, methemoglobin and carboxyhemoglobin as prognosis biomarkers in critically ill patients with COVID-19: An observational prospective study. Viruses 13, 2445 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13122445</ArticleId><ArticleId IdType="pubmed">34960714</ArticleId><ArticleId IdType="pmc">8709066</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi, G. &amp; Henry, B. M. Pooled analysis of mid-regional pro-adrenomedullin values in COVID-19 patients with critical illness. Intern. Emerg. Med. 16, 1723–1725 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-021-02756-2</ArticleId><ArticleId IdType="pubmed">33963517</ArticleId><ArticleId IdType="pmc">8104917</ArticleId></ArticleIdList></Reference><Reference><Citation>Laudanski, K. et al. Dynamic changes in central and peripheral neuro-injury vs. Neuroprotective serum markers in covid-19 are modulated by different types of anti-viral treatments but do not affect the incidence of late and early strokes. Biomedicines 9, (2021).</Citation></Reference><Reference><Citation>Kanberg, N. et al. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. EBioMedicine 70, 103512 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103512</ArticleId><ArticleId IdType="pubmed">34333238</ArticleId><ArticleId IdType="pmc">8320425</ArticleId></ArticleIdList></Reference><Reference><Citation>Roback, J. D. &amp; Guarner, J. Convalescent plasma to treat COVID-19. JAMA 323, 1561 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.4940</ArticleId><ArticleId IdType="pubmed">32219429</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezagholizadeh, A., Khiali, S., Sarbakhsh, P. &amp; Entezari-Maleki, T. Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. Eur. J. Pharmacol. vol. 897. https://doi.org/10.1016/j.ejphar.2021.173926 (2021).</Citation></Reference><Reference><Citation>Wu, C. et al. Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: A cohort study with propensity score analysis. Crit. Care 24, (2020).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>